All Pages

All Pages

Overview

NeuroWiki is a comprehensive knowledge base for neurodegenerative disease mechanisms, focusing on Alzheimer's Disease (AD), Parkinson's Disease (PD), and related disorders. The wiki maps molecular pathways, protein interactions, and cellular mechanisms involved in neurodegeneration, linking genes to proteins to pathways to disease phenotypes [1](https://pubmed.ncbi.nlm.nih.gov/23674168/).

All Pages

Overview

NeuroWiki is a comprehensive knowledge base for neurodegenerative disease mechanisms, focusing on Alzheimer's Disease (AD), Parkinson's Disease (PD), and related disorders. The wiki maps molecular pathways, protein interactions, and cellular mechanisms involved in neurodegeneration, linking genes to proteins to pathways to disease phenotypes [1](https://pubmed.ncbi.nlm.nih.gov/23674168/).

This index provides navigation to all sections of NeuroWiki. The platform contains pages across multiple categories covering genetic risk factors, protein products, cellular mechanisms, therapeutic approaches, clinical trials, and research institutions [2](https://pubmed.ncbi.nlm.nih.gov/35788534/).

Section Index

The following table summarizes the main content sections in NeuroWiki:

| Section | Pages | Description |
|---------|-------|-------------|
| [Genes](/genes) | 3855 | Genetic risk factors, disease genes, and GWAS loci for AD, PD, ALS, FTD |
| [Cell Types](/cell-types) | 3573 | Neuronal subtypes, glial cells, and cell-type specific mechanisms |
| [Proteins](/proteins) | 3183 | Protein products, therapeutic targets, and protein aggregates |
| [Mechanisms](/mechanisms) | 1619 | Molecular pathways, disease mechanisms, and biological processes |
| [Therapeutics](/therapeutics) | 999 | Drug candidates, therapeutic modalities, and treatment approaches |
| [Diseases](/diseases) | 476 | Disease pages including AD, PD, ALS, FTD, Huntington's disease |
| [Companies](/companies) | 554 | Pharmaceutical and biotechnology companies in neurodegeneration |
| [Institutions](/institutions) | 292 | Research universities, hospitals, and consortia |
| [Clinical Trials](/clinical-trials) | 441 | Active and completed clinical trials for neurodegenerative diseases |
| [Researchers](/researchers) | 210 | Key researchers and their publications in the field |
| [Ideas](/ideas) | 198 | Novel therapeutic concepts and research hypotheses |
| [Entities](/entities) | 182 | Drug candidates, biological entities, and therapeutic molecules |
| [Biomarkers](/biomarkers) | 161 | Diagnostic and prognostic biomarkers for neurodegenerative diseases |
| [Technologies](/technologies) | 155 | Research tools, methodologies, and technological platforms |
| [Experiments](/experiments) | 170 | Key experiments and research findings |
| [Investment](/investment) | 97 | Investment analysis, funding trends, and market data |
| [Events](/events) | 64 | Scientific conferences, meetings, and symposia |
| [Brain Regions](/brain-regions) | 52 | Anatomical brain regions and their involvement in disease |
| [Diagnostics](/diagnostics) | 80 | Diagnostic methods, imaging techniques, and clinical assessments |
| [Knowledge Gaps](/gaps) | 50 | Identified gaps in knowledge requiring further research |
| [Hypotheses](/hypotheses) | 72 | Research hypotheses and theoretical frameworks |
| [Circuits](/circuits) | 29 | Neural circuits and connectivity maps |
| [Datasets](/datasets) | 22 | Public datasets and data repositories |
| [Projects](/projects) | 21 | Research programs and initiatives |
| [Organizations](/organizations) | 22 | Research foundations and patient advocacy groups |

Content Statistics and Growth

NeuroWiki has grown substantially since its inception, now containing over 15,000 total pages. The content is organized to facilitate both breadth of coverage and depth of mechanistic understanding.

Content Growth by Year

• 2024: Major expansion of gene and protein pages following the completion of large-scale GWAS studies
• 2025: Addition of cell-type specific mechanisms and circuit-level analyses
• 2026: Continued expansion of therapeutic approaches and clinical trial coverage

Content Quality Metrics

The wiki employs several quality indicators:

• Word count: Target of 3000+ words per page for comprehensive coverage
• References: Target of 20+ PubMed references per page for scientific rigor
• Cross-linking: Dense internal linking to create a connected knowledge graph

Quick Links

Top Categories by Size

• [Genes](/genes) — 3855 pages covering genetic risk factors for neurodegenerative diseases
• [Cell Types](/cell-types) — 3573 pages describing neuronal and glial cell types
• [Proteins](/proteins) — 3183 pages on protein products and therapeutic targets
• [Mechanisms](/mechanisms) — 1619 pages detailing molecular pathways and disease mechanisms
• [Therapeutics](/therapeutics) — 999 pages on drug development and treatment approaches
• [Diseases](/diseases) — 476 pages covering specific neurodegenerative disorders

Disease Research

• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD is the most common neurodegenerative disorder, affecting over 55 million people globally. Key topics include amyloid plaque formation, tau pathology, neuroinflammation, and synaptic dysfunction [3](https://pubmed.ncbi.nlm.nih.gov/14570856/).
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD affects approximately 10 million people worldwide, characterized by dopaminergic neuron loss and alpha-synuclein aggregation [4](https://pubmed.ncbi.nlm.nih.gov/25904081/).
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — ALS is a rapidly progressive motor neuron disease with limited treatment options [5](https://pubmed.ncbi.nlm.nih.gov/15866179/).
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — FTD encompasses a spectrum of disorders characterized by frontotemporal lobe degeneration [6](https://pubmed.ncbi.nlm.nih.gov/27041082/).

Therapeutic Approaches

• [Therapeutics Overview](/therapeutics) — Comprehensive hub for treatment approaches
• [Clinical Trials](/clinical-trials) — Active and recruiting trials for neurodegenerative diseases
• [Biomarkers](/biomarkers) — Diagnostic and prognostic biomarkers including Aβ, tau, and alpha-synuclein

Research Resources

• [Genes](/genes) — Genetic risk factors including APOE, LRRK2, GBA, and APP
• [Proteins](/proteins) — Protein targets including amyloid-beta, tau, and alpha-synuclein
• [Mechanisms](/mechanisms) — Disease mechanisms including protein aggregation, neuroinflammation, mitochondrial dysfunction
• [Cell Types](/cell-types) — Cell-type specific mechanisms in neurons, astrocytes, and microglia
• [Brain Regions](/brain-regions) — Regional vulnerability in substantia nigra, hippocampus, cortex

Detailed Category Breakdown

Genes Section

The genes section contains 3855 pages covering:

• AD Risk Genes: APP, APOE, PSEN1, PSEN2, TREM2, CLU, PICALM, CR1
• PD Risk Genes: LRRK2, GBA, SNCA, PARK2, PARK7, PINK1, DJ-1, GIGYF2
• ALS Risk Genes: C9orf72, SOD1, FUS, TARDBP, ANG, ALS2
• FTD Risk Genes: MAPT, GRN, C9orf72, TBK1, VCP

• Gene function and expression patterns
• Disease associations and risk alleles
• Protein products and biological pathways
• Therapeutic implications

Proteins Section

The proteins section contains 3183 pages covering:

• Aggregation Proteins: Amyloid-beta, tau, alpha-synuclein, TDP-43
• Therapeutic Targets: BACE1, gamma-secretase, LRRK2, GCase
• Transport Proteins: DAT, VMAT2, EAATs
• Signaling Proteins: mTOR, AMPK, MAPK pathways

Mechanisms Section

The mechanisms section contains 1619 pages covering:

• Protein Aggregation: Nucleation, propagation, and clearance mechanisms
• Neuroinflammation: Microglial activation, complement system, cytokine signaling
• Mitochondrial Dysfunction: Complex I deficiency, PINK1/Parkin mitophagy
• Synaptic Dysfunction: Vesicle cycling, spine morphology, neurotransmission
• Cellular Stress: ER stress, oxidative stress, DNA damage response

Therapeutics Section

The therapeutics section contains 999 pages covering:

• Disease-Modifying Therapies: Antibodies, small molecules, gene therapies
• Symptomatic Treatments: Dopaminergic agents, cholinesterase inhibitors
• Emerging Approaches: RNA therapeutics, cell replacement, immunomodulation

Navigation Tips

Finding Specific Topics

Understanding Page Structure

Each wiki page typically contains:

• Title and summary: Overview of the topic
• Mechanistic details: In-depth explanation of biological processes
• Clinical relevance: Disease associations and therapeutic implications
• References: PubMed-linked citations for scientific claims

Related Sections

• [Home](/home) — NeuroWiki main entry point
• [Genes](/genes) — Genetic risk factors and disease genes
• [Proteins](/proteins) — Protein products and therapeutic targets
• [Mechanisms](/mechanisms) — Molecular pathways and disease mechanisms
• [Therapeutics](/therapeutics) — Therapeutic approaches and treatments

Coverage Statistics

NeuroWiki provides extensive coverage across neurodegenerative diseases, with detailed documentation of disease mechanisms, genetic risk factors, therapeutic approaches, and clinical trials [7](https://pubmed.ncbi.nlm.nih.gov/31186534/).

• Alzheimer's Disease: Complete coverage of genetics, pathology, biomarkers, and clinical trials. Key topics include amyloid plaque formation and clearance [8](https://pubmed.ncbi.nlm.nih.gov/36248431/), tau hyperphosphorylation and neurofibrillary tangle formation, neuroinflammation mediated by microglia and astrocytes, synaptic loss and cognitive decline, and emerging disease-modifying therapies targeting amyloid and tau [9](https://pubmed.ncbi.nlm.nih.gov/29394541/).
• Parkinson's Disease: Comprehensive documentation of genetic forms including LRRK2, GBA, SNCA, and PARK2 mutations. Coverage includes alpha-synuclein aggregation and Lewy body formation, dopaminergic neuron degeneration in the substantia nigra, mitochondrial dysfunction and PINK1/Parkin mitophagy pathways, and Lewy body dementia progression [10](https://pubmed.ncbi.nlm.nih.gov/32080426/).
• ALS: Coverage of major genetic causes including C9orf72 repeat expansions, SOD1 mutations, FUS, and TARDBP. Documentation includes TDP-43 proteinopathy, excitotoxicity mechanisms, RNA metabolism dysregulation, and emerging therapeutic approaches including antisense oligonucleotides [11](https://pubmed.ncbi.nlm.nih.gov/32778813/).
• FTD: Documentation of tau and TDP-43 pathology, genetic forms including GRN, MAPT, and C9orf72, and therapeutic development for this heterogeneous disorder.
• Atypical Parkinsonisms: Coverage of Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Multiple System Atrophy (MSA), including 4R-tauopathies and alpha-synucleinopathies respectively.

Content Organization Principles

NeuroWiki follows several key organizational principles to ensure comprehensive and accessible coverage of neurodegenerative disease research.

Hierarchical Structure

The wiki employs a hierarchical organization that mirrors the biological hierarchy from genes to systems:

Cross-Linking Strategy

Every page contains extensive internal links to related topics, creating a dense knowledge graph. This enables:

• Navigation from gene to protein to pathway to disease
• Discovery of related mechanisms across different diseases
• Identification of shared therapeutic targets
• Tracing of disease-specific vulnerabilities

Evidence-Based Content

All content is supported by peer-reviewed literature, with explicit citations to PubMed. The wiki prioritizes:

• Recent publications (post-2020) for current understanding
• Foundational reviews for background concepts
• Primary research for specific findings
• Clinical trial data for therapeutic approaches

Related Index Pages

NeuroWiki provides multiple navigation paths to access content:

Primary Hubs

• [Home](/home) — Main entry point with featured content
• [All Pages](/all-pages) — This comprehensive index
• [Diseases](/diseases) — Disease-specific landing pages
• [Mechanisms](/mechanisms) — Pathway and process documentation

Category Indexes

• [Genes Index](/genes) — Browse genetic risk factors
• [Proteins Index](/proteins) — Browse protein products
• [Cell Types Index](/cell-types) — Browse cellular components
• [Therapeutics Index](/therapeutics) — Browse treatment approaches
• [Clinical Trials Index](/clinical-trials) — Browse clinical studies

Specialized Indexes

• [Companies Index](/companies) — Pharmaceutical and biotech companies
• [Institutions Index](/institutions) — Research organizations
• [Biomarkers Index](/biomarkers) — Diagnostic and prognostic markers
• [Investment Index](/investment) — Market and funding analysis

Technical Infrastructure

Content Management

NeuroWiki uses a git-based content management system:

• Markdown files with YAML frontmatter for content
• Git repository for version control and collaboration
• Automated sync to Wiki.js database
• Quality validation on content submission

Search and Discovery

The platform provides multiple search mechanisms:

• Full-text search across all pages
• Category-specific filtering
• Tag-based navigation
• Cross-reference tracking

Content Standards

All pages follow standardized formatting:

• Consistent heading hierarchy
• Unified reference formatting
• Standardized internal linking
• Structured metadata in frontmatter

Future Development

NeuroWiki continues to evolve with the neurodegenerative disease research field. Planned expansions include:

Emerging Topics

• Tau propagation mechanisms and strain diversity
• Alpha-synuclein prion-like spread
• Microglial heterogeneity and disease states
• Astrocyte reactivity and neurodegeneration
• Neurovascular unit dysfunction
• Glymphatic system and sleep-dependent clearance

New Content Types

• Interactive pathway diagrams
• Gene-disease relationship visualizations
• Clinical trial outcome summaries
• Therapeutic target validation status
• Patient stratification biomarkers
• Computational models and simulations

Enhanced Features

• Automated reference updates
• Machine learning-assisted content generation
• Integration with external databases
• Real-time literature alerts
• API access for programmatic queries

Research Methodology in NeuroWiki

NeuroWiki documents the key research approaches used to investigate neurodegenerative diseases, providing context for how knowledge is generated and validated.

Experimental Approaches

Molecular Biology Techniques

• Genomics: GWAS, whole exome sequencing, and targeted sequencing to identify risk variants
• Transcriptomics: RNA-seq, single-cell RNA-seq, and spatial transcriptomics to characterize gene expression changes
• Proteomics: Mass spectrometry-based proteomics to identify protein alterations and post-translational modifications
• Metabolomics: Metabolic profiling to identify biochemical pathway disruptions

Cellular and Animal Models

• In vitro models: Cell lines, primary neurons, iPSC-derived neurons and glia
• Transgenic models: Mouse models expressing mutant APP, tau, alpha-synuclein, SOD1
• Knockout models: Genetic deletion of disease-relevant genes
• Viral models: AAV-mediated gene delivery to model pathology

Imaging and Neuropathology

• Neuroimaging: MRI, PET, CT for in vivo assessment
• Electron microscopy: Ultrastructural analysis of protein aggregates
• Light microscopy: Histological staining and immunohistochemistry
• Super-resolution microscopy: Nanoscale localization of pathological proteins

Clinical Research Methods

Clinical Trials

• Trial phases: Phase I through Phase IV designs
• Endpoint measures: Cognitive, functional, and biomarker endpoints
• Patient selection: Inclusion and exclusion criteria, genetic stratification
• Statistical approaches: Sample size, power analysis, adaptive designs

Biomarker Studies

• Fluid biomarkers: CSF and blood-based markers (Aβ42/40, p-tau, NfL, α-syn)
• Imaging biomarkers: Amyloid PET, tau PET, FDG-PET, dopamine transporter imaging
• Clinical biomarkers: Motor and cognitive assessments

Therapeutic Development Pipeline

NeuroWiki provides comprehensive coverage of the drug development pipeline for neurodegenerative diseases, from target identification through clinical approval.

Target Discovery

Genetic Targets

• Amyloid precursor protein (APP) processing: BACE1 and gamma-secretase inhibitors
• Tau protein: Kinases, aggregation inhibitors, and immunotherapy
• Alpha-synuclein: Aggregation blockers, antibodies, and gene silencing
• TREM2: Agonistic antibodies to enhance microglial function

Pathway Targets

• Neuroinflammation: TLR signaling, complement system, cytokine pathways
• Mitochondrial function: PINK1/Parkin mitophagy, mitochondrial dynamics
• Protein clearance: Autophagy-lysosome pathway, ubiquitin-proteasome system
• Synaptic function: Synaptic vesicle proteins, receptor trafficking

Drug Modalities

Small Molecules

• Enzyme inhibitors: BACEi, MAO-B inhibitors, COMT inhibitors
• Receptor modulators: NMDA antagonists, dopamine agonists
• Aggregation inhibitors: Tau and α-syn small molecule modulators

Biologics

• Monoclonal antibodies: Anti-Aβ, anti-tau, anti-α-syn antibodies
• Engineered proteins: Trimeric ligands, bispecific antibodies
• Enzyme replacement: GCase augmentation for GBA carriers

Gene and Cell Therapies

• Gene therapy: AAV-mediated gene delivery (GBA, LRRK2, SNCA)
• Antisense oligonucleotides: ASO targeting toxic proteins
• Cell therapy: Stem cell transplantation for neuronal replacement
• RNAi: siRNA and shRNA for gene silencing

Clinical Development

Alzheimer's Disease Pipeline

• Amyloid-targeting: Lecanemab, donanemab, and next-generation antibodies
• Tau-targeting: Immunotherapies and small molecule inhibitors
• Neuroprotective: Synaptic modulators, mitochondrial protectors
• Metabolic: GLP-1 agonists, insulin sensitizers
• Anti-inflammatory: Microglial modulators, complement inhibitors

Parkinson's Disease Pipeline

• Alpha-synuclein: Antibodies, aggregation inhibitors, vaccines
• Disease modification: Neuroprotective agents beyond symptomatic treatment
• Levodopa delivery: Extended-release formulations, continuous infusion
• Genetic therapies: AAV-GBA, LRRK2 inhibitors, SNCA silencing

Contributing to NeuroWiki

NeuroWiki welcomes contributions from researchers, clinicians, and students in the neurodegenerative disease field. Content is maintained through a git-based workflow with peer review of major changes. Contributors can:

For contribution guidelines, see the GitHub repository or contact the editorial team.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
• [APOE4-Selective Lipid Nanoemulsion Therapy](/hypothesis/h-c9c79e3e) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE Isoform Conversion Therapy](/hypothesis/h-15336069) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: APOE
• [APOE Isoform Expression Across Glial Subtypes](/hypothesis/h-seaad-fa5ea82d) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: APOE
• [VCP-Mediated Autophagy Enhancement](/hypothesis/h-18a0fcc6) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: VCP
• [RNA-Binding Competition Therapy for TDP-43 Cross-Seeding](/hypothesis/h-7693c291) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: TARDBP

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;